High-dose chemotherapy and autologous peripheral blood stem cell transfusion for adult and adolescent patients with small round cell sarcomas

K. Yamada, M. Takahashi, M. Ogura, Y. Kagami, H. Taji, Y. Kamiya, H. Sugiura, Y. Morishima

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

The treatment of small-round-cell tumors (SRCT) in adult patients remains a challenge to clinicians. In the present study, we analyzed the feasibility and efficacy of high-dose chemotherapy (HDCT) followed by autologous peripheral blood stem-cell rescue as a consolidation therapy exclusively for patients with good disease control through a single regimen of induction chemotherapy and local therapy. Twenty-one patients (12 females, median age 22.0 years) were analyzed, including seven cases with rhabdomyosarcoma (RMS) and 14 cases with Ewing's family tumors (EFT). Overall, survival was 46% and failure-free survival (FFS) was 33% at 3 years. Patients with EFT had better FFS than those with RMS, with an estimated 3-year FFS of 50% (P<0.01). There was a single case of possible treatment-related death and two cases of secondary malignancies. This study cannot conclusively determine the beneficial effects of HDCT for improving treatment outcomes in adult SRCTs due to the small number of subjects. However, study findings suggest that a subgroup of patients with EFT may obtain prolonged survival benefits from this therapy.

Original languageEnglish
Pages (from-to)471-476
Number of pages6
JournalBone Marrow Transplantation
Volume39
Issue number8
DOIs
Publication statusPublished - 04-2007
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'High-dose chemotherapy and autologous peripheral blood stem cell transfusion for adult and adolescent patients with small round cell sarcomas'. Together they form a unique fingerprint.

Cite this